User profiles for "author:Antoni Ribas"
Antoni RibasUCLA Verified email at mednet.ucla.edu Cited by 164680 |
Cancer immunotherapy using checkpoint blockade
A Ribas, JD Wolchok - Science, 2018 - science.org
The release of negative regulators of immune activation (immune checkpoints) that limit
antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in …
antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in …
[HTML][HTML] Primary, adaptive, and acquired resistance to cancer immunotherapy
P Sharma, S Hu-Lieskovan, JA Wargo, A Ribas - Cell, 2017 - cell.com
Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these …
cancers of a wide range of histologies. Broadening the clinical applicability of these …
Classifying cancers based on T-cell infiltration and PD-L1
Cancer immunotherapy may become a major treatment backbone in many cancers over the
next decade. There are numerous immune cell types found in cancers and many …
next decade. There are numerous immune cell types found in cancers and many …
[HTML][HTML] Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert… - … England Journal of …, 2011 - Mass Medical Soc
Background Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib
(PLX4032) have shown response rates of more than 50% in patients with metastatic …
(PLX4032) have shown response rates of more than 50% in patients with metastatic …
PD-1 blockade induces responses by inhibiting adaptive immune resistance
PC Tumeh, CL Harview, JH Yearley, IP Shintaku… - Nature, 2014 - nature.com
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented
rates of durable clinical responses in patients with various cancer types,,,,. One mechanism …
rates of durable clinical responses in patients with various cancer types,,,,. One mechanism …
[HTML][HTML] Pembrolizumab versus ipilimumab in advanced melanoma
C Robert, J Schachter, GV Long… - … England Journal of …, 2015 - Mass Medical Soc
Background The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment
for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 …
for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 …
[HTML][HTML] Genetic basis for clinical response to CTLA-4 blockade in melanoma
A Snyder, V Makarov, T Merghoub… - … England Journal of …, 2014 - Mass Medical Soc
Background Immune checkpoint inhibitors are effective cancer treatments, but molecular
determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies …
determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies …
[HTML][HTML] Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma
O Hamid, C Robert, A Daud, FS Hodi… - … England Journal of …, 2013 - Mass Medical Soc
Background The programmed death 1 (PD-1) receptor is a negative regulator of T-cell
effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 …
effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 …
[HTML][HTML] Inhibition of mutated, activated BRAF in metastatic melanoma
Background The identification of somatic mutations in the gene encoding the serine–
threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to …
threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to …
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Therapeutics that are designed to engage RNA interference (RNAi) pathways have the
potential to provide new, major ways of imparting therapy to patients,. Long, double …
potential to provide new, major ways of imparting therapy to patients,. Long, double …